Cellectis (Cellectis) FCF Margin % : -11,230.97% (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Cellectis FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Cellectis's Free Cash Flow for the three months ended in Sep. 2023 was $-17.41 Mil. Cellectis's Revenue for the three months ended in Sep. 2023 was $0.16 Mil. Therefore, Cellectis's FCF Margin % for the quarter that ended in Sep. 2023 was -11,230.97%.

As of today, Cellectis's current FCF Yield % is -36.20%.

The historical rank and industry rank for Cellectis's FCF Margin % or its related term are showing as below:

CLLS' s FCF Margin % Range Over the Past 10 Years
Min: -573.56 Med: -303.82 Max: 191.3
Current: -404.55

During the past 13 years, the highest FCF Margin % of Cellectis was 191.30%. The lowest was -573.56%. And the median was -303.82%.

CLLS's FCF Margin % is ranked worse than
64.15% of 1032 companies
in the Biotechnology industry
Industry Median: -148.935 vs CLLS: -404.55

Cellectis FCF Margin % Historical Data

The historical data trend for Cellectis's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis FCF Margin % Chart

Cellectis Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

FCF Margin %

Get a 7-Day Free Trial

-573.58

-540.49

-244.21

-405.71

-468.86

Cellectis Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
FCF Margin %	Get a 7-Day Free Trial															-15,161.93	-9.22	-20,531.65	-10,789.39	-11,230.97

Competitive Comparison of Cellectis's FCF Margin %

For the Biotechnology subindustry, Cellectis's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cellectis's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectis's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Cellectis's FCF Margin % falls into.

Cellectis FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Cellectis's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-89.885	/	19.171
	=	-468.86 %

Cellectis's FCF Margin for the quarter that ended in Sep. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-17.408	/	0.155
	=	-11,230.97 %

Cellectis FCF Margin % Related Terms

Thank you for viewing the detailed overview of Cellectis's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cellectis (Cellectis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (NAS:CLLS) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

CMVLF:USA 0WA2:UK ALCLS:France ZVAA:Germany

Address

8, rue de la Croix Jarry, Paris, FRA, 75013

Website

https://www.cellectis.com

Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.